Core Viewpoint - Ganli Pharmaceutical has received approval from the Ethiopian Food and Drug Authority for its insulin products, indicating a significant step in expanding its market presence in Ethiopia [1]. Group 1 - The company announced the receipt of registration certificates for Glargine Insulin Injection and Glargine Insulin Injection Pre-filled Pen [1]. - The registration numbers for the products are 11865/13208/NMR/2025 and 11864/13210/NMR/2025, respectively [1].

Core Viewpoint - Ganli Pharmaceutical has received regulatory approval for its insulin products in Ethiopia, marking a significant milestone for the company in expanding its market presence in the region [1]. Company Summary - Ganli Pharmaceutical (603087) announced on January 15 that it has obtained the registration approval for Glargine Insulin Injection and Glargine Insulin Injection Pre-filled Pen from the Ethiopian National Food and Drug Administration [1]. - The approved Glargine Insulin is a long-acting insulin that requires subcutaneous injection once daily, providing a sustained hypoglycemic effect for 24 hours [1]. - The characteristics of Glargine Insulin include a long duration of action, stable blood concentration without peaks, and smooth glucose control [1].

Group 1 - Siyuan Electric reported a total operating revenue of 21.205 billion yuan for 2025, a year-on-year increase of 37.18%, with a net profit attributable to shareholders of 3.163 billion yuan, up 54.35% year-on-year [1] - VisiOn expects a negative net profit for 2025, indicating a loss in operating performance [2] - Chongqing Steel anticipates a net loss of 2.5 billion to 2.8 billion yuan for 2025, which is an improvement from a net loss of 3.196 billion yuan in the previous year [3] - Lianfa Co. forecasts a net profit of 280 million to 320 million yuan for 2025, representing a year-on-year growth of 38.92% to 58.77% [4] Group 2 - CICC announced that the audit work related to the absorption merger with Dongxing Securities and Xinda Securities has not yet been completed [5] - Dalong Real Estate's subsidiary won a project bid worth 763 million yuan [6] - Zhongchuang Zhiling plans to issue convertible bonds to raise no more than 4.35 billion yuan for various projects [7] - Jintong Co. intends to acquire a 24% stake in Jinsha Molybdenum for 1.731 billion yuan [8] Group 3 - Nami Technology expects a net profit of 128 million to 145 million yuan for 2025, an increase of 54.51% to 75.03% year-on-year [9] - China State Construction reported a new contract total of 4.5458 trillion yuan for 2025, a 1% increase year-on-year [12] - China Metallurgical Group's new contract amount for 2025 is expected to decrease by 10.8% to 1.1136 trillion yuan [13] Group 4 - Beiding Co. reported a net profit of 111 million yuan for 2025, a year-on-year increase of 59.05% [14] - Southwest Securities expects a net profit of 1.028 billion to 1.098 billion yuan for 2025, an increase of 47% to 57% [15] - China Eastern Airlines reported a 4.93% year-on-year increase in passenger capacity for December 2025 [20] Group 5 - *ST Aowei's stock may be delisted due to a closing price below par value [21] - Yilian Network expects a net profit of 2.542 billion to 2.648 billion yuan for 2025, a decrease of 0% to 4% year-on-year [22] - Huochen Co. anticipates a net profit of 420 million to 540 million yuan for 2025, recovering from a loss of 2 million yuan in the previous year [17] Group 6 - Guoli Electronics expects a net profit of 68 million to 80 million yuan for 2025, an increase of 124.89% to 164.57% [28] - Jinchuan Group forecasts a net profit of 11 billion to 12 billion yuan for 2025, a year-on-year increase of 73.57% to 89.34% [41] - Triangle Tire plans to invest 3.219 billion yuan in a new tire project in Cambodia [42]

Group 1 - The core point of the article is that Ganli Pharmaceutical has received regulatory approval for its insulin products in Ethiopia, which is a significant milestone for the company [1] Group 2 - Ganli Pharmaceutical announced on January 15 that it received the registration approval for Glargine Insulin Injection and Glargine Insulin Injection Pre-filled Pen from the Ethiopian National Food and Drug Administration [1] - Glargine insulin is a long-acting insulin that is injected subcutaneously once daily, providing a blood sugar-lowering effect that lasts for 24 hours [1] - The characteristics of Glargine insulin include a long duration of action, stable blood concentration without peaks, and smooth blood sugar control [1]

一、药物基本情况 1、药品名称：Basalin TM 甘李药业股份有限公司 关于甘精胰岛素注射液及其预填充注射笔获得埃塞 俄比亚药品注册批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，甘李药业股份有限公司（以下简称"公司"、"甘李药业"）收到埃 塞俄比亚国家食品药品监督管理局（Ethiopian Food and Drug Authority）核准签 发的甘精胰岛素注射液及甘精胰岛素注射液预填充注射笔注册批件（批件号： 11865/13208/NMR/2025、11864/13210/NMR/2025）。现将相关情况公告如下： 证券代码：603087 证券简称：甘李药业 公告编号：2026-005 2、药品通用名：甘精胰岛素注射液、甘精胰岛素注射液预填充注射笔 3、适应症：糖尿病 4、剂型：注射剂 5、规格：3ml：100 units/ml（卡式瓶）、3ml：100 units/ml（预填充注射笔） 6、批件号：11865/13208/NMR/2025、11864/13210/NMR/2025 7、申请人：甘 ...

Core Viewpoint - The company has received regulatory approval from the Ethiopian National Food and Drug Administration for its insulin products, indicating a significant step in expanding its market presence in Ethiopia [1] Group 1: Product Approval - The company announced the approval of its Glargine Insulin Injection and Glargine Insulin Injection Pre-filled Pen registration certificates [1] - The product is named BasalinTM, indicated for diabetes treatment, and is available in two forms: 3ml at 100 units/ml in vial and 3ml at 100 units/ml in pre-filled pen [1] - Glargine insulin is a long-acting insulin that requires subcutaneous injection once daily, providing a blood sugar-lowering effect that lasts for 24 hours [1]

Core Viewpoint - Gan Li Pharmaceutical has received approval from the Ethiopian Food and Drug Authority for the registration of Glargine Insulin Injection and Glargine Insulin Injection Pre-filled Pen, indicating a significant step in expanding its product offerings in the Ethiopian market [1] Company Summary - The approved products include Glargine Insulin Injection and its pre-filled pen, with registration numbers 11865/13208/NMR/2025 and 11864/13210/NMR/2025 respectively [1] - Glargine Insulin is a long-acting insulin that requires subcutaneous injection once daily, providing a blood sugar-lowering effect that lasts for 24 hours [1] - The characteristics of Glargine Insulin include a long duration of action, stable blood concentration without peaks, and smooth glucose control [1]

Core Viewpoint - Gan Li Pharmaceutical has received approval from the European Commission for its insulin injection product, marking its entry into the European market [1] Group 1: Product Approval - Gan Li Pharmaceutical's insulin injection, named Ondibta in the EU and Changxiulin in China, is approved for the treatment of diabetes in adults, adolescents, and children aged 2 years and older [1] - The product will be marketed in the European Union, Iceland, Liechtenstein, and Norway [1]

Group 1: Regulatory Developments - The National Healthcare Security Administration (NHSA) is soliciting public opinions on the "Guidelines for Real-World Comprehensive Value Assessment of Drugs" to establish a unified national evaluation system [1] - Huadong Medicine's subsidiary received FDA approval for clinical trials of DR10624, a novel drug targeting metabolic-associated fatty liver disease [1] - Fosun Pharma's subsidiary has had its drug registration application for erythromycin lactobionate injection accepted by the National Medical Products Administration [2] - Stone Pharmaceutical's new drug for hypertension has received FDA approval for clinical trials in the U.S. [3] - Zhi Mei Ru Kang's siRNA therapy for ALS has entered Phase 2 clinical trials [4] Group 2: Market and Corporate Developments - Cap Bio's major shareholders have increased their stake from 31.52% to 33.05% following capital changes and share buybacks [5] - Bluestar Medical's product is expected to be selected for national centralized procurement of drug-coated balloons, which could enhance its market presence [7] - NVIDIA and Eli Lilly have announced a $1 billion collaboration to establish an AI innovation lab focused on drug discovery and development [8] - Dr. Wang Qiang has transitioned from Xiansheng Pharmaceutical to Ganli Pharmaceutical as Senior Vice President and Chief Strategy Officer [9] Group 3: Quality Control and Safety - China Resources Double Crane has addressed recent quality issues with sodium bicarbonate injection products, clarifying that non-compliance was due to packaging issues during transport [10]

Core Viewpoint - Gan & Lee Pharmaceuticals has received marketing authorization from the European Commission for its insulin glargine injection (brand name: Ondibta?), which is intended for the treatment of diabetes in adults, adolescents, and children aged 2 years and older [1][3]. Group 1: Product Information - The insulin glargine injection is a long-acting insulin that requires subcutaneous injection once daily, providing a stable blood concentration and effective glucose control for 24 hours [1][4]. - The product is available in a pre-filled pen format with a concentration of 100 units/ml in a 3ml vial [4]. Group 2: Market Context - According to the International Diabetes Federation, there are approximately 588.7 million diabetes patients aged 20-79 globally, with 65.6 million in Europe, representing 11.1% of the global patient population [2]. - The total medical expenditure due to diabetes is estimated at $193 billion globally, with an average annual expenditure of $2,951 per patient [2]. - Sanofi is currently the main supplier of insulin glargine in Europe, with projected global sales of €2.855 billion (approximately $2.989 billion) for 2024, including €819 million (approximately $857 million) in Europe [2]. Group 3: Financial Investment - As of September 30, 2025, Gan & Lee Pharmaceuticals has invested a total of ¥936 million in research and development for the insulin glargine project [3].